Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) was down 3.3% during mid-day trading on Thursday . The company traded as low as $20.84 and last traded at $20.87, with a volume of 526,560 shares trading hands. The stock had previously closed at $21.58.

Several equities research analysts have recently weighed in on SUPN shares. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a report on Wednesday. Northland Securities reiterated an “outperform” rating and issued a $22.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, March 11th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $24.00 price target on shares of Supernus Pharmaceuticals in a report on Saturday, April 2nd. TheStreet upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 29th. Finally, Jefferies Group reiterated a “buy” rating and issued a $23.00 price target (up from $19.00) on shares of Supernus Pharmaceuticals in a report on Thursday, May 12th. Five research analysts have rated the stock with a buy rating, Supernus Pharmaceuticals presently has an average rating of “Buy” and an average target price of $23.00.

The stock has a market cap of $1.02 billion and a P/E ratio of 60.95. The stock has a 50-day moving average of $19.17 and a 200 day moving average of $15.52.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, May 3rd. The specialty pharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.09 by $0.01. During the same quarter last year, the firm posted $0.02 EPS. The company earned $43 million during the quarter, compared to the consensus estimate of $45.33 million. The company’s revenue was up 53.0% compared to the same quarter last year. Equities analysts expect that Supernus Pharmaceuticals Inc. will post $0.62 EPS for the current year.

In related news, VP Padmanabh P. Bhatt sold 30,762 shares of Supernus Pharmaceuticals stock in a transaction dated Monday, April 11th. The stock was sold at an average price of $16.49, for a total value of $507,265.38. Following the sale, the vice president now directly owns 57,306 shares in the company, valued at approximately $944,975.94. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

A number of large investors have recently bought and sold shares of SUPN. Kornitzer Capital Management Inc. KS boosted its stake in Supernus Pharmaceuticals by 49.5% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 1,245,170 shares of the specialty pharmaceutical company’s stock valued at $16,735,000 after buying an additional 412,280 shares during the last quarter. California State Teachers Retirement System boosted its stake in Supernus Pharmaceuticals by 579.2% in the fourth quarter. California State Teachers Retirement System now owns 424,712 shares of the specialty pharmaceutical company’s stock valued at $5,708,000 after buying an additional 362,178 shares during the last quarter. Russell Frank Co boosted its stake in Supernus Pharmaceuticals by 109.0% in the fourth quarter. Russell Frank Co now owns 648,277 shares of the specialty pharmaceutical company’s stock valued at $8,871,000 after buying an additional 338,145 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Supernus Pharmaceuticals during the fourth quarter valued at $2,345,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Supernus Pharmaceuticals by 12.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,087,055 shares of the specialty pharmaceutical company’s stock valued at $14,610,000 after buying an additional 117,574 shares in the last quarter.

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.